Alnylam Pharmaceuticals Inc (ALNY)
269.06
-1.96
(-0.72%)
USD |
NASDAQ |
Mar 28, 14:03
Alnylam Pharmaceuticals Enterprise Value: 33.42B for March 27, 2025
View 4,000+ Financial Data Types:
Add
Browse
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Pfizer Inc | 185.21B |
| Biomarin Pharmaceutical Inc | 13.35B |
| BridgeBio Pharma Inc | 7.973B |
| Regeneron Pharmaceuticals Inc | 62.48B |
| Vertex Pharmaceuticals Inc | 122.93B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -83.76M |
| Revenue (Quarterly) | 593.17M |
| Total Expenses (Quarterly) | 698.32M |
| EPS Diluted (Quarterly) | -0.65 |
| Gross Profit Margin (Quarterly) | 82.67% |
| Profit Margin (Quarterly) | -14.12% |
| Earnings Yield | -0.81% |
| Normalized Earnings Yield | -0.4081 |